Q: Your work in discovering the role of cholesterol crystals on cardiovascular attacks is renowned. Could you tell us about the impact that this made on how we view and treat plaque?
Article By:
The inaugural Donald Fredrickson Conference on Familial Lipoprotein Disorders was convened on Sunday, April 29, 2018 at the end of the National Lipid Association Annual Scientific Sessions in Las Vegas. The meeting was chaired by Dr. Virgil Brown.
Article By:
The Midwest Lipid Association is 510 members strong and represents Indiana, Illinois, Wisconsin, Michigan, Ohio, Kansas, Iowa, Missouri, North Dakota, South Dakota, Minnesota and Nebraska. We are pleased to have David R. Neff, DO, FNLA, serving as our President this year. We have an active and diverse group and Sanford A. Carimi, MD, FNLA, our Immediate Past President, took time at our February meeting to acknowledge the great MWLA representation on national level projects. Ann M.
Article By:
Background
Article By:
Volanesorsen is a novel pharmacotherapy designed to treat patients with Familial Chylomicronemia Syndrome (FCS). This is a highly comorbid disease without any currently available pharmacotherapies to help reduce triglycerides or the more feared complication, pancreatitis. This has left a void in treatment that volanesorsen has attempted to address.
Article By:
COMMITTEE NOTE TO MEMBERS OF THE NATIONAL LIPID ASSOCIATION: At the request of the NLA President, the NLA Board of Directors, the Science and Policy Council, the Practice Management Council and the Health Quality and Research Committee, it is with pleasure that the 2017-18 NLA Therapeutics Committee presents a Special Report on how to best incorporate PCSK9 Inhibitors into routine clinical lipid practice by integrating best available evidence into the routine process of care.
Article By:
Lipodystrophies are a group of disorders of fat tissue loss that are classified according to whether the condition is genetic or acquired and by the distribution of fat loss, either generalized or partial (Table 1).1 Generalized lipodystrophy is a rare, complex, and clinically heterogeneous disorder characterized by the widespread loss of adipose tissue.
Article By:
The William and Sonja Connor Chair of Preventive Cardiology
Professor of Medicine and Physiology & Pharmacology
Director, Center for Preventive Cardiology
Knight Cardiovascular Institute
Oregon Health & Science University
Portland, OR
Diplomate, American Board of Clinical Lipidology
What is the Structure of Lp(a)?
Article By:
Our healthcare organization has designated “population health management” as a core part of our strategy planning and accountability. This is reflected through the implementation of what is defined as the “quadruple aim:”
–providing health care which is affordable, improves the patient experience from the standpoint of quality and satisfaction in terms of outcomes, and also supports the physicians and providers of that healthcare in their life goals and personal quality–
Article By:
Greetings from those of us at the Midwest Lipid Association (MWLA). We all trust that you had an excellent summer as we head into cooler weather and color changes up here in the Midwest and Canada. For those of you who do not know, our Canadian partners who are National Lipid Association (NLA) members are represented through the MWLA Chapter. It’s our pleasure to bring you this issue of LipidSpin.